FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  TOBIN JAMES R						2. Issuer Name and Ticker or Trading Symbol GLOBUS MEDICAL INC [ GMED ]							5. Relationship of Repo (Check all applicable) X Director			n(s) to Iss	
(Last) (First) (Middle)  VALLEY FORGE BUSINESS CENTER  2560 GENERAL ARMISTEAD AVENUE						3. Date of Earliest Transaction (Month/Day/Year) 03/15/2022								(give title		Other (s below)	specify
(Street) AUDUBON PA 19403 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)							i. Indiv ine) X	ividual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person				
		Tab	le I - N	on-Deriva	ative	Securities Ac	quire	d, Di	sposed o	of, or Bo	enefici	ally	Owned	l			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day)				/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a			and 5) Secu Bene Own		Amount of ecurities eneficially wned Following eported		Direct of the condinect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code	v	Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)				msu. 4)
Class A Common Stock 03/15/2					022		M		5,308	A	\$43.	3.58		5,308		)	
Class A Common Stock 03/15/20					022		M		3,542	A	\$53.	3.27 8,850		850	D		
Class A Common Stock 03/15/20							S		8,850	D	\$65.471 <sup>(1)</sup>		0		Γ	)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date,		I. Fransact Code (In: 3)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		De Se (In	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficial Owned Following Reported	ly Di	O. wnership orm: irect (D) r Indirect ) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy Class A Common Stock)	\$43.58	03/15/2022		М			5,308	(2)	01/22/2029	Class A Common Stock	5,308	\$0.00	5,208	D	
Stock Option (Right to Buy Class A Common Stock)	\$53.27	03/15/2022		М			3,542	(3)	01/22/2030	Class A Common Stock	3,542	\$0.00	21,458	D	

## **Explanation of Responses:**

- 1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$65.09 to \$66.05, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- 2. These options were granted on January 22, 2019 and are fully vested.
- 3. These options were granted on January 22, 2020 and are fully vested.

## Remarks:

/s/ Kelly G. Huller, Attorney-

03/17/2022

in-Fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.